Form 4: Fennec Pharmaceuticals Director Chris A. Rallis Reports Stock Transactions

Director Chris A. Rallis of Fennec Pharmaceuticals reports exercising options and selling shares to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Summary

• On February 14, 2025, Chris A. Rallis, a director of Fennec Pharmaceuticals, exercised options to acquire 1,992 common shares at a price of $2.51 per share.
• The director then sold 1,186 common shares at $6.82 per share to satisfy tax obligations related to the option exercise.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on August 17, 2023.
• Following these transactions, Rallis directly owns 53,020 common shares and 182,706 options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports required insider trading activity. The transactions are part of a pre-planned trading strategy.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into the transactions of those with privileged information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company director.
• The impact is likely minimal as the transactions are part of a pre-arranged trading plan.

Key Dates